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The two major cytochrome P450 polymor-
phisms, with respect to variable drug response, 
are those of CYP2C19 and CYP2D6. Both 
gene variations can cause abolished, reduced, 
normal or increased enzyme expression trans-
lating into the poor (PM), intermediate (IM), 
extensive (EM) and ultrarapid (UM) metab-
olizer phenotypes [1]. Multiple gene copies 
of CYP2D6 emerged in Ethiopia and North 
Africa in order to make the inactivation of the 
toxic plant alkaloids this enzyme metabolizes 
more efficient [2]; evaluation of the Neander-
thal sequences reveals defect CYP genes [3]; 
these data indicate a long history of poly-
morphism in these genes. Although these 
polymorphisms are not causing an apparent 
pheno type, accumulating evidence indicates 
that they can influence brain function.
CYP2D6 in the brain
CYP2D6 has been found in neurons in 
numerous human brain areas, including the 
thalamus, hypothalamus, hippocampus, sub-
stantia nigra, cerebellum, and in several lay-
ers of the frontal neocortex [4,5] raising ques-
tions about its potential role in these neurons. 
The enzyme was implicated in metabolism 
of the endogenous compounds 5-methoxy-
tryptamine, anandamide, progesterone and 
tyramine and in generation of serotonin and 
dopamine from trace amines [6].
This hypothesis is strengthened by the 
fact that in a transgenic mouse model, with 
CYP2D6 expressed in the brain, higher sero-
tonin levels have been measured in several 
brain regions, including the cerebellum and 
hippocampus [7]. CYP2D6 might also affect 
the endocannabinoid system within the CNS 
due to its ability to metabolize anandamide 
and its derivatives [8]; however, the physi-
ological significance of such metabolism is 
still unclear.
CYP2D6 & brain phenotypes
Associations between CYP2D6 genotypes 
and personality traits gave the first indica-
tions that CYP2D6 might have endogenous 
functions apart from its important role in 
drug metabolism. In one of the first reports, it 
was shown that PMs displayed higher impul-
sivity-related traits [9], which was confirmed 
by a later study [10]. Others have found PMs 
to be more anxiety-prone and less successful 
in socialization when compared with EMs 
[11,12]. These heterogeneous results might be 
related to different ethnicities of the subjects 
and different methods used for monitoring 
the personality, but do suggest that CYP2D6 
might have an endogenous role in the human 
brain influencing behavior.
The UM CYP2D6 phenotype has been 
suggested to predict suicidal risk [13,14] and 
increased suicidal behavior among individu-
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als with eating disorders [15]. In search for a physiologi-
cal effect of higher CYP2D6 brain expression in such 
individuals, Stingl and collaborators examined the 
perfusion rates in the thalamus and the right hippo-
campus among healthy human subjects. They detected 
an effect of CYP2D6 polymorphism on resting-state 
perfusion in the thalamus, hypothalamus, posterior 
cerebral cortex, and isolated parts of the medial tempo-
ral lobe and orbitofrontal cortex, where PMs had lower 
perfusion rates, a pattern that suggested an association 
with brain circuits involved in vigilance. Also, they 
tested the effect of the CYP2D6 polymorphism on 
a standard working-memory task and recognition of 
facial expressions, a task eliciting neural circuits related 
with the detection of emotionally arousing stimuli 
measured with fMRI. In both studies they found an 
effect of the CYP2D6 polymorphism in visual areas 
in the posterior cerebral cortex, whereas no effect 
could be detected in areas outside of those staked out 
by the previous perfusion study (see [16] and references 
therein). This provides an interesting mechanistic link 
to the findings concerning a relationship to suicide.
CYP2C19 expression in the developmental 
brain
Expression of CYP2C19 in humans has long been 
thought to be restricted to the liver and small intestine 
[1]; however, using a transgenic mouse model with 12 
gene copies of the CYP2C19 gene it was shown that 
the human CYP2C19 gene is expressed in fetal brain 
and silenced completely 1 week after birth [17]. Analy-
ses of human fetal brain samples showed relatively high 
cortical expression levels of CYP2C19, around 0.5% of 
that seen in adult liver [17]. Altogether, these data indi-
cate a transient fetal brain expression of CYP2C19 that 
might affect development.
Like CYP2D6, CYP2C19 has broad substrate speci-
ficity and it metabolizes many different classes of psy-
chotropic drugs, including selective serotonin-reuptake 
inhibitors, tricyclic antidepressants such as amitrip-
tyline, benzodiazepines such as diazepam, and the 
 anticonvulsant drug mephenytoin [1].
CYP2C19 & brain phenotypes
CYP2C19 polymorphism was associated with depressive 
mode in humans in study encompassing 1742 twins. 
Twins carrying allelic variants causing high activity 
of the enzyme (CYP2C19*1) showed more depressive 
symptoms than the subjects carrying a defective allelic 
variant (CYP2C19*2), based on their significantly lower 
T1 scores in the center for epidemiologic studies depres-
sion (CES-D) scale and lower scores on the subscales 
depressed mood, psychomotor retardation, and somatic 
complaints, compared with extensive metabolizers [18].
The effect of the CYP2C19 genotypes on brain 
function and morphology was studied in the CYP2C19 
transgenic mice. As adults they showed decreased 
hippocampal volume, an anxious phenotype, and 
increased hippocampal activation after acute stress [17]. 
The reduction in the hippocampal volume appears to 
be directly caused by CYP2C19 expression; the homo-
zygotes were showing a more dramatic reduction of 
hippocampal volume [60%] than hemizygotes [12%] 
after birth. Reduced hippo campal volumes are com-
monly observed in several neuropsychiatric disorders 
including post-traumatic stress disorder, schizophre-
nia, and major depression (see [17] and references 
therein).
Adult CYP2C19 hemizygotes showed increased 
stress sensitivity and increased anxiety-like behavior. 
Stressful life events and stress sensitivity are major 
risk factors for psychiatric diseases making this ani-
mal a model of interest for factors involved in the 
regulation of stress response. These mice also showed 
a reduced number of GABAergic interneurons in the 
dentate gyrus of the hippocampus, the region in which 
α2GABA
A
 and not α3GABA
A
 receptors are present 
[19]. Anxiolytic effects of benzodiazepines are mediated 
by GABA
A
 receptor subtypes containing α2 and α3 
subunits [20]; therefore, it might be plausible that the 
reduced number of GABAergic interneurons in the 
dentate gyrus leads to hippocampus over-activation in 




CYP2C19 has been shown to metabolize cannabi-
noid compounds [21], previously shown to be impor-
tant for the successful migration of GABAergic neu-
rons to the hippocampus [22]. During hippocampal 
development, CB1 is present in GABA interneurons 
[23]; therefore, it can be hypothesized that the reduced 
number of GABA interneurons observed in CYP2C19 
transgenic mice is caused by impaired cannabinoid 
signaling in developing hippocampus.
A role of CYP2C19 in the metabolism of endo-
genous substances during brain development seems to 
be a likely explanation for the phenotypes observed in 
the transgenic mouse model; however, the identities of 
these substances remain to be discovered.
Synergy of increased CYP2C19 & CYP2D6 
activity
CYP2D6 and CYP2C19 have to a great extent over-
lapping substrate specificities. A recent study by Ller-
ena and collaborators examining suicide risk among 
subjects having both high CYP2D6 and CYP2C19 
expression is interesting [24]. Thus, patients with a high 
CYP2D6-CYP2C19 metabolic capacity showed an 
increased risk for a severe suicide attempt as measured 
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by the SIS-objective circumstance subscale, particu-
larly in absence of a family history of suicide. Those 
with no family history of suicide are less vulnerable and 
consequently may need more stressful triggers to pre-
cipitate it, indicating that having a higher CYP2D6-
CYP2C19 metabolic capacity can be associated with 
the increased sensitivity to these triggers.
Conclusion
Increasing evidence suggest that the polymorphic 
enzymes CYP2C19 and CYP2D6 indeed have endo-
genous functions in the development and regulation 
of specific neuronal pathways, translating into inter-
individual differences in cognition and risk for depres-
sion and suicide. Enzyme-coding gene polymorphisms 
determine metabolic rates of a large number of psycho-
tropic drugs modifying their concentrations at the 
site of action and can predict a need for adjustments 
in dosage. Since the enzymes also metabolize endo-
genous psychotropic substances, it is very likely that 
the observed brain phenotypes involve their altered 
metabolism at different stages of brain development 
and during adulthood. Although being a difficult task, 
the identification of these compounds would provide 
an important knowledge for the molecular and cellular 
control of phenotypic alterations and lay a ground for 
possible future pharmacologic interventions.
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